Eficácia do monitoramento contínuo da glicose no manejo do diabetes mellitus tipo 2 em adultos
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Comparar a eficácia do monitoramento contínuo da glicose (MCG) com tratamentos tradicionais para diabetes mellitus tipo 2. Métodos: Trata-se de uma revisão integrativa da literatura realizada através das bases PubMED, Biblioteca Virtual em Saúde (BVS) e Periódico CAPES, usando os descritores: “Adults”, “Continuous Glucose Monitoring”, “Diabetes Mellitus, Type 2” e “Treatment Outcome” e obtendo o truncamento de pesquisa: (Continuous Glucose Monitoring) AND (Diabetes Mellitus, Type 2) AND (Treatment Outcome) AND (Adults). Foram encontrados 1.104 artigos, filtrados conforme critérios de inclusão (idiomas português, inglês e espanhol; período de 2019 a 2024; artigos completos) e exclusão (artigos duplicados, resumos, fora do escopo). Resultados: O MCG permite monitoramento em tempo real, reduzindo episódios de hipoglicemia e melhorando o controle glicêmico, embora o alto custo seja um desafio. Aliado à telemedicina, o MCG melhora a adesão ao tratamento e a qualidade de vida dos pacientes. Em contraste, métodos tradicionais enfrentam limitações como imprecisão e desconforto das punções diárias, afetando a adesão e a eficácia do tratamento. Considerações finais: O MCG é superior aos métodos tradicionais, oferecendo maior precisão e conforto. Sua adoção, com políticas de saúde e treinamento adequado, pode transformar o manejo do diabetes tipo 2, proporcionando cuidados mais eficazes e personalizados.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ARADÓTTIR TB, et al. Feasibility of a new approach to initiate insulin in type 2 diabetes. Journal of diabetes science and technology, 2021; 15(2): 339–345.
3. BAKER M, et al. Practical implementation of remote continuous glucose monitoring in hospitalized patients with diabetes. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 2022; 79(6): 452–458.
4. CASTELLANA M, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. BMJ open diabetes research & care, 2020; 8(1): 001092.
5. CHAO C, et al. Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN). Endocrinology, diabetes & metabolism, 2023; 6(3): 414.
6. DIXON RF, et al. A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits. Journal of diabetes science and technology, 2020; 14(5): 908–911.
7. EHRHARDT N, et al. Effectiveness of a culturally tailored diabetes education curriculum with real-time continuous glucose monitoring in a Latinx population with type 2 diabetes: the CUT-DM with CGM for Latinx randomised controlled trial study protocol. BMJ open, 2023; 13(12): 82005.
8. GERBER BS, et al. Mobile health intervention in patients with type 2 diabetes: A randomized clinical trial. JAMA network open, 2023; 6(9): 2333629.
9. HAAK T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: A multicenter, open-label randomized controlled trial. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2017; 8(1): 55–73.
10. JANCEV M, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia, 2024; 67(5): 798–810.
11. KARTER AJ, et al. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA: the journal of the American Medical Association, 2021; 325(22): 2273–2284.
12. KAWAGUCHI Y, et al. Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring. Journal of diabetes investigation, 2024; 15(5): 598–607.
13. LIND N, et al. Peer support for adults with type 2 diabetes starting continuous glucose monitoring-An exploratory randomised controlled trial. Diabetic medicine: a journal of the British Diabetic Association, 2024; 41(6): 15321.
14. LIND N, et al. Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial. BMJ open, 2021; 11(1): 40648.
15. MATSUOKA A, et al. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study. Journal of diabetes investigation, 2020; 11(2): 417–425.
16. MUNAN M, et al. Acute and chronic effects of exercise on continuous glucose monitoring outcomes in type 2 diabetes: A meta-analysis. Frontiers in endocrinology, 2020; 11: 495.
17. OSER TK, et al. Personal continuous glucose monitoring use among adults with type 2 diabetes: Clinical efficacy and economic impacts. Current diabetes reports, 2021; 21(11).
18. RIBEIRO RT, et al. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy. Nutrition, metabolism, and cardiovascular diseases: NMCD, 2021; 31(4): 1267–1275.
19. RIVERA-ÁVILA DA, et al. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC endocrine disorders, 2021; 21(1): 79.
20. RUAN Y, et al. Association of body fat percentage with time in range generated by continuous glucose monitoring during continuous subcutaneous insulin infusion therapy in type 2 diabetes. Journal of diabetes research, 2021; 2021: 1–9.
21. SINGH LG, et al. Continuous glucose monitoring in general wards for prevention of hypoglycemia: Results from the glucose telemetry system pilot study. Journal of diabetes science and technology, 2020; 14(4): 783–790.
22. TAYLOR PJ, et al. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review. Journal of diabetes investigation, 2028; 9(4): 713–725.
23. YAJIMA T, et al., Comparison of interstitial fluid glucose levels obtained by continuous glucose monitoring and flash glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. Journal of diabetes science and technology, 2020; 14(6): 1088–1094.
24. ZHENG M, et al. Comparing effects of continuous glucose monitoring systems (CGMs) and self-monitoring of blood glucose (SMBG) amongst adults with type 2 diabetes mellitus: a systematic review protocol. Systematic reviews, 2020; 9(1).